Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
10.1038/nrd1902
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Drug Discovery (297)
Bibliography

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005). Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 4(12), 988–1004.

Authors 5
  1. Bryan T. Hennessy (first)
  2. Debra L. Smith (additional)
  3. Prahlad T. Ram (additional)
  4. Yiling Lu (additional)
  5. Gordon B. Mills (additional)
References 182 Referenced 1,741
  1. Fruman, D. A., Meyers, R. E. & Cantley, L. C. Phosphoinositide kinases. Annu. Rev. Biochem. 67, 481–507 (1998). Excellent review of the structure and function of PI3Ks. (10.1146/annurev.biochem.67.1.481) / Annu. Rev. Biochem. by DA Fruman (1998)
  2. Hiles, I. D. et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 70, 419–429 (1992). (10.1016/0092-8674(92)90166-A) / Cell by ID Hiles (1992)
  3. Jimenez, C. et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 17, 743–753 (1998). (10.1093/emboj/17.3.743) / EMBO J. by C Jimenez (1998)
  4. Pawson, T. & Nash, P. Protein–protein interactions define specificity in signal transduction. Genes. Dev. 14, 1027–1047 (2000). (10.1101/gad.14.9.1027) / Genes. Dev. by T Pawson (2000)
  5. Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000). (10.1042/bj3510095) / Biochem. J. by SP Davies (2000)
  6. Oudit, G. Y. et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell Cardiol. 37, 449–471 (2004). (10.1016/j.yjmcc.2004.05.015) / J. Mol. Cell Cardiol. by GY Oudit (2004)
  7. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A. & Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963–10968 (1999). (10.1074/jbc.274.16.10963) / J. Biol. Chem. by L Bi (1999)
  8. Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C. & Cantley, L. C. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25, 1596–1607 (2005). (10.1128/MCB.25.5.1596-1607.2005) / Mol. Cell. Biol. by SM Brachmann (2005)
  9. Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297, 1031–1034 (2002). (10.1126/science.1073560) / Science by K Okkenhaug (2002)
  10. Bilancio, A. et al. Key role of the p110δ isoform of PI3K in B cell antigen and IL4 receptor signalling- comparative analysis of genetic and pharmacological interference with p110δ function in B cells. Blood. 2005 Sep 22; [Epub ahead of print]. (10.1182/blood-2005-07-3041)
  11. Northcott, C. A. et al. Upregulated function of phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial hypercontractility. Clin. Exp. Pharmacol. Physiol. 32, 851–858 (2005). (10.1111/j.1440-1681.2010.04276.x) / Clin. Exp. Pharmacol. Physiol. by CA Northcott (2005)
  12. Condliffe, A. M. et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432–1440 (2005). (10.1182/blood-2005-03-0944) / Blood by AM Condliffe (2005)
  13. Sujobert, P. et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063–1066 (2005). (10.1182/blood-2004-08-3225) / Blood by P Sujobert (2005)
  14. Yip, S. C. et al. Over-expression of the p110β but not p110α isoform of PI 3-kinase inhibits motility in breast cancer cells. Cell Motil. Cytoskeleton 59, 180–188 (2004). (10.1002/cm.20032) / Cell Motil. Cytoskeleton by SC Yip (2004)
  15. Geng, L. et al. A specific antagonist of the p110δ catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res. 64, 4893–4899 (2004) (10.1158/0008-5472.CAN-03-3955) / Cancer Res. by L Geng (2004)
  16. Campbell, M. et al. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ. Res. 95, 380–388 (2004). (10.1161/01.RES.0000138019.82184.5d) / Circ. Res. by M Campbell (2004)
  17. Gukovsky, I. et al. Phosphatidylinositide 3-kinase γ regulates key pathologic responses to cholecystokinin in pancreatic acinar cells. Gastroenterology 126, 554–566 (2004). (10.1053/j.gastro.2003.11.017) / Gastroenterology by I Gukovsky (2004)
  18. Leverrier, Y. et al. Class I phosphoinositide 3-kinase p110β is required for apoptotic cell and Fcγ receptor-mediated phagocytosis by macrophages. J. Biol. Chem. 278, 38437–38442 (2003). (10.1074/jbc.M306649200) / J. Biol. Chem. by Y Leverrier (2003)
  19. Chantry, D. et al. p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. 272, 19236–19241 (1997). (10.1074/jbc.272.31.19236) / J. Biol. Chem. by D Chantry (1997)
  20. Perrino, C. et al. Targeted inhibition of β-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves β-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J. Am. Coll. Cardiol. 45, 1862–1870 (2005). (10.1016/j.jacc.2005.02.062) / J. Am. Coll. Cardiol. by C Perrino (2005)
  21. Jackson, S. P. et al. PI3-kinase p110β: a new target for antithrombotic therapy. Nature Med. 11, 507–514 (2005). (10.1038/nm1232) / Nature Med. by SP Jackson (2005)
  22. Coffer, P. J. & Woodgett, J. R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. 201, 475–81 (1991). (10.1111/j.1432-1033.1991.tb16305.x) / Eur. J. Biochem. by PJ Coffer (1991)
  23. Bellacosa, A., Testa, J. R., Staal, S. P. & Tsichlis, P. N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254, 274–77 (1991). (10.1126/science.1833819) / Science by A Bellacosa (1991)
  24. Murthy, S. S., Tosolini, A., Taguchi, T. & Testa, J. R. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet. Cell Genet. 88, 39–40 (2000). (10.1159/000015481) / Cytogenet. Cell Genet. by SS Murthy (2000)
  25. Alessi, D. R. et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541–551 (1996). (10.1002/j.1460-2075.1996.tb01045.x) / EMBO J. by DR Alessi (1996)
  26. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–65 (2001). (10.1038/35077225) / Nature by P Blume-Jensen (2001)
  27. Lynch, D. K., Ellis, C. A., Edwards, P. A. & Hiles, I. D. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 18, 8024–32 (1999). (10.1038/sj.onc.1203258) / Oncogene by DK Lynch (1999)
  28. Kawakami, Y. et al. Protein kinase C βII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J. Biol. Chem. 279, 47720–5 (2004). (10.1074/jbc.M408797200) / J. Biol. Chem. by Y Kawakami (2004)
  29. Sarbassov dos, D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–101 (2005). (10.1126/science.1106148) / Science by D Sarbassov dos (2005)
  30. Arboleda, M. J. et al. Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63, 196–206 (2003). / Cancer Res. by MJ Arboleda (2003)
  31. Yang, Z. Z. et al. Protein kinase B α/Akt1 regulates placental development and fetal growth. J. Biol. Chem. 278, 32124–31 (2003). (10.1074/jbc.M302847200) / J. Biol. Chem. by ZZ Yang (2003)
  32. Peng, X. D. et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17, 1352–65 (2003). (10.1101/gad.1089403) / Genes Dev. by XD Peng (2003)
  33. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349–52 (2001). (10.1074/jbc.C100462200) / J. Biol. Chem. by H Cho (2001)
  34. Testa, J. R. & Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl Acad. Sci. USA 98, 10983–985 (2001). (10.1073/pnas.211430998) / Proc. Natl Acad. Sci. USA by JR Testa (2001)
  35. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002). (10.1038/nrc839) / Nature Rev. Cancer by I Vivanco (2002)
  36. Luo, J., Manning, B. D. & Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257–62 (2003). (10.1016/S1535-6108(03)00248-4) / Cancer Cell by J Luo (2003)
  37. Chen, X. et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20, 6073–83 (2001). (10.1038/sj.onc.1204736) / Oncogene by X Chen (2001)
  38. Wang, Q. et al. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J. Biol. Chem. 277, 36602–610 (2002). (10.1074/jbc.M206306200) / J. Biol. Chem. by Q Wang (2002)
  39. Carroll, P. E. et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18, 1935–44 (1999). (10.1038/sj.onc.1202515) / Oncogene by PE Carroll (1999)
  40. Toi, M., Saji, S., Suzuki, A., Yamamoto, Y., Tominaga, T. MDM2 in Breast Cancer. Breast Cancer 25, 264–68 (1997). (10.1007/BF02966519) / Breast Cancer by M Toi (1997)
  41. Sherr, C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94–99 (2000). (10.1016/S0959-437X(99)00038-6) / Curr. Opin. Genet. Dev. by CJ Sherr (2000)
  42. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857–68 (1999). Excellent review of some of the downstream mechanisms of AKT action. (10.1016/S0092-8674(00)80595-4) / Cell by A Brunet (1999)
  43. Cahill, C. M. et al. Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14–3-3-dependent and 14–3-3-independent pathways. J. Biol. Chem. 276, 13402–10 (2001). (10.1074/jbc.M010042200) / J. Biol. Chem. by CM Cahill (2001)
  44. Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337 (2004). (10.1038/nature02369) / Nature by HG Wendel (2004)
  45. Schmelzle, T. & Hall, M. N. TOR, a central controller of cell growth. Cell 103, 253–262 (2000). Excellent review of mTOR and its activity. (10.1016/S0092-8674(00)00117-3) / Cell by T Schmelzle (2000)
  46. Lazaris-Karatzas, A., Montine, K. S. & Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345, 544–547 (1990). (10.1038/345544a0) / Nature by A Lazaris-Karatzas (1990)
  47. Polunovsky, V. A. et al. Translational control of the antiapoptotic function of Ras. J. Biol. Chem. 275, 24776–24780 (2000). (10.1074/jbc.M001938200) / J. Biol. Chem. by VA Polunovsky (2000)
  48. Potter, C. J., Pedraza, L. G. & Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nature Cell Biol. 4, 658–665 (2002). (10.1038/ncb840) / Nature Cell Biol. by CJ Potter (2002)
  49. Tee, A. R. et al. Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl Acad. Sci. USA 99, 13571–576 (2002). (10.1073/pnas.202476899) / Proc. Natl Acad. Sci. USA by AR Tee (2002)
  50. Dan, H. C. et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277, 35364–35370 (2002). (10.1074/jbc.M205838200) / J. Biol. Chem. by HC Dan (2002)
  51. Hengstschlager, M., Rosner, M., Fountoulakis, M. & Lubec, G. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels. Biochem. Biophys. Res. Commun. 312, 676–83 (2003). (10.1016/j.bbrc.2003.10.170) / Biochem. Biophys. Res. Commun. by M Hengstschlager (2003)
  52. Harrington, L. S. et al. The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213–23 (2004). (10.1083/jcb.200403069) / J. Cell Biol. by LS Harrington (2004)
  53. Zhang, H. et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112, 1223–1233 (2003). (10.1172/JCI200317222) / J. Clin. Invest. by H Zhang (2003)
  54. Sun, S. Y. et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052–7058 (2005). (10.1158/0008-5472.CAN-05-0917) / Cancer Res. by SY Sun (2005)
  55. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 8, 179–183 (2005). (10.1016/j.ccr.2005.08.008) / Cancer Cell. by N Hay (2005)
  56. Hardie, D. G., Scott, J. W., Pan, D. A. & Hudson, E. R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546, 113–120 (2003). (10.1016/S0014-5793(03)00560-X) / FEBS Lett. by DG Hardie (2003)
  57. Shaw, R. J. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101, 3329–3335 (2004). (10.1073/pnas.0308061100) / Proc. Natl Acad. Sci. USA by RJ Shaw (2004)
  58. Shaw, R. J. et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91–99 (2004). (10.1016/j.ccr.2004.06.007) / Cancer Cell by RJ Shaw (2004)
  59. Fujita, N., Sato, S. & Tsuruo, T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 278, 49254–49260 (2003). (10.1074/jbc.M306614200) / J. Biol. Chem. by N Fujita (2003)
  60. Shin, I. et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nature Med. 8, 1145–1152 (2002). (10.1038/nm759) / Nature Med. by I Shin (2002)
  61. Zhou, B. P. et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biol. 3, 245–252 (2001). (10.1038/35060032) / Nature Cell Biol. by BP Zhou (2001)
  62. Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499–3511 (1998). (10.1101/gad.12.22.3499) / Genes Dev. by JA Diehl (1998)
  63. Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991–5004 (2004). (10.1200/JCO.2004.05.061) / J. Clin. Oncol. by WY Kim (2004)
  64. Skinner, H. D., Zheng, J. Z., Fang, J., Agani, F. & Jiang, B. H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem. 279, 45643–51 (2004). (10.1074/jbc.M404097200) / J. Biol. Chem. by HD Skinner (2004)
  65. Zhang, D. & Brodt, P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 22, 974–82 (2003). (10.1038/sj.onc.1206197) / Oncogene by D Zhang (2003)
  66. Kimura, A. et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 23, 4505–15 (2004). (10.1038/sj.onc.1207582) / Oncogene by A Kimura (2004)
  67. Remy, I., Montmarquette, A. & Michnick, S. W. PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3. Nature Cell Biol. 6, 358–65 (2004). (10.1038/ncb1113) / Nature Cell Biol. by I Remy (2004)
  68. Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926–35 (2004). (10.1093/jnci/djh166) / J. Natl Cancer Inst. by J Shou (2004)
  69. Mondesire, W. H. et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10, 7031–42 (2004). (10.1158/1078-0432.CCR-04-0361) / Clin. Cancer Res. by WH Mondesire (2004)
  70. Knuefermann, C. et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22, 3205–12 (2003). (10.1038/sj.onc.1206394) / Oncogene by C Knuefermann (2003)
  71. Gupta, A. K. et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int. J. Radiat. Oncol. Biol. Phys. 56, 846–53 (2003). (10.1016/S0360-3016(03)00214-1) / Int. J. Radiat. Oncol. Biol. Phys. by AK Gupta (2003)
  72. Brognard, J., Clark, A. S., Ni, Y. & Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61, 3986–97 (2001). / Cancer Res. by J Brognard (2001)
  73. Kim, D. et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 10, 975–87 (2005). (10.2741/1592) / Front Biosci. by D Kim (2005)
  74. Stoica, G. E. et al. Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22, 7998–8011 (2003). (10.1038/sj.onc.1206769) / Oncogene by GE Stoica (2003)
  75. Mendez, P., Azcoitia, I. & Garcia-Segura, L. M. Estrogen receptor α forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. Brain Res. Mol. Brain Res. 112, 170–6 (2003). (10.1016/S0169-328X(03)00088-3) / Brain Res. Mol. Brain Res. by P Mendez (2003)
  76. Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117–127 (2004). Excellent review of the role of PTEN in trastuzumab resistance in breast cancer. (10.1016/j.ccr.2004.06.022) / Cancer Cell by Y Nagata (2004)
  77. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000). Excellent review of neoplastic progression due to the collective role of multiple genetic and molecular abnormalities. (10.1016/S0092-8674(00)81683-9) / Cell by D Hanahan (2000)
  78. Bachman, K. E. et al. The PIK3CA Gene is Mutated with High Frequency in Human Breast Cancers. Cancer Biol. Ther. 3, 772–775 (2004). (10.4161/cbt.3.8.994) / Cancer Biol. Ther. by KE Bachman (2004)
  79. Kang, S., Bader, A. G. & Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl Acad. Sci. USA 102, 802–807 (2005). Excellent paper which demonstrates that PI3K mutations are oncogenic in human cancers. (10.1073/pnas.0408864102) / Proc. Natl Acad. Sci. USA by S Kang (2005)
  80. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004). (10.1126/science.1096502) / Science by Y Samuels (2004)
  81. Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678–7681 (2004). (10.1158/0008-5472.CAN-04-2933) / Cancer Res. by IG Campbell (2004)
  82. Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99–102 (1999). (10.1038/5042) / Nature Genet. by L Shayesteh (1999)
  83. Woenckhaus, J. et al. Genomic gain of PIK3CA and increased expression of p110α are associated with progression of dysplasia into invasive squamous cell carcinoma. J. Pathol. 198, 335–342 (2002). (10.1002/path.1207) / J. Pathol. by J Woenckhaus (2002)
  84. Ma, Y. Y. et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19, 2739–2744 (2000). (10.1038/sj.onc.1203597) / Oncogene by YY Ma (2000)
  85. Mizoguchi, M., Nutt, C. L., Mohapatra, G. & Louis, D. N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 14, 372–377 (2004). (10.1111/j.1750-3639.2004.tb00080.x) / Brain Pathol. by M Mizoguchi (2004)
  86. Broderick, D. K. et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64, 5048–5050 (2004). (10.1158/0008-5472.CAN-04-1170) / Cancer Res. by DK Broderick (2004)
  87. Jucker, M. et al. Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 16, 894–901 (2002). (10.1038/sj.leu.2402484) / Leukemia by M Jucker (2002)
  88. Cheng, J. Q. et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93, 3636–3341 (1996). (10.1073/pnas.93.8.3636) / Proc. Natl Acad. Sci. USA by JQ Cheng (1996)
  89. Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q. & Testa, J. R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81–86 (1998). (10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R) / Mol. Carcinog. by BA Ruggeri (1998)
  90. Bellacosa, D. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995). (10.1002/ijc.2910640412) / Int. J. Cancer by D Bellacosa (1995)
  91. Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl Acad. Sci. USA 84, 5034–5037 (1987). (10.1073/pnas.84.14.5034) / Proc. Natl Acad. Sci. USA by SP Staal (1987)
  92. Eng, C. PTEN: one gene, many syndromes. Hum. Mutat. 22, 183–198 (2003). (10.1002/humu.10257) / Hum. Mutat. by C Eng (2003)
  93. Li, Y. L., Tian, Z., Wu, D. Y., Fu, B. Y. & Xin, Y. Loss of heterozygosity on 10q23. 3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J. Gastroenterol. 11, 285–288 (2005). (10.3748/wjg.v11.i2.285) / World J. Gastroenterol. by YL Li (2005)
  94. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997). (10.1126/science.275.5308.1943) / Science by J Li (1997)
  95. Cairns, P. et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997–5000 (1997). / Cancer Res. by P Cairns (1997)
  96. Garcia, J. M. et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res. Treat. 57, 237–243 (1999). (10.1023/A:1006273516976) / Breast Cancer Res. Treat. by JM Garcia (1999)
  97. Khan, S. et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int. J. Cancer 112, 407–410 (2004). (10.1002/ijc.20447) / Int. J. Cancer by S Khan (2004)
  98. Goel, A. et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 64, 3014–3021 (2004). (10.1158/0008-5472.CAN-2401-2) / Cancer Res. by A Goel (2004)
  99. Stephens, P. et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nature Genet. 37, 590–592 (2005). (10.1038/ng1571) / Nature Genet. by P Stephens (2005)
  100. Davies, H. et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65, 7591–7595 (2005). (10.1158/0008-5472.CAN-05-1855) / Cancer Res. by H Davies (2005)
  101. Parsons, D. W. et al. Colorectal cancer: mutations in a signalling pathway. Nature 436, 792 (2005). (10.1038/436792a) / Nature by DW Parsons (2005)
  102. Wang, Z. et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 304, 1164–1166 (2004). (10.1126/science.1096096) / Science. by Z Wang (2004)
  103. Rodriguez-Viciana, P. et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457–467 (1997). (10.1016/S0092-8674(00)80226-3) / Cell by P Rodriguez-Viciana (1997)
  104. Almoguera, C. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549–554 (1988). (10.1016/0092-8674(88)90571-5) / Cell by C Almoguera (1988)
  105. Yanez, L., Groffen, J. & Valenzuela, D. M. c-K-ras mutations in human carcinomas occur preferentially in codon 12. Oncogene 1, 315–318 (1987). / Oncogene by L Yanez (1987)
  106. Nelson, M. A., Wymer, J. & Clements, N. Jr. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett 103, 115–121 (1996). (10.1016/0304-3835(96)04202-4) / Cancer Lett by MA Nelson (1996)
  107. Davies, H. A. et al. Mutations of the BRAF gene in human cancer. Nature. 417, 949–954 (2002). (10.1038/nature00766) / Nature. by HA Davies (2002)
  108. Rolitsky, C. D., Theil, K. S., McGaughy, V. R., Copeland, L. J. & Niemann, T. H. HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 18, 138–143 (1999). (10.1097/00004347-199904000-00007) / Int. J. Gynecol. Pathol. by CD Rolitsky (1999)
  109. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989). (10.1126/science.2470152) / Science by DJ Slamon (1989)
  110. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004). Excellent paper which demonstrates that HER2 mutations occur in 10% human lung cancers (10.1038/431525b) / Nature by P Stephens (2004)
  111. Klos, K. S. et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98, 1377–1385 (2003). (10.1002/cncr.11656) / Cancer by KS Klos (2003)
  112. Nicholson, K. M., Streuli, C. H. & Anderson, N. G. Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines. Breast Cancer Res. Treat. 81, 117–128 (2003). (10.1023/A:1025765215765) / Breast Cancer Res. Treat. by KM Nicholson (2003)
  113. Ekstrand, A. J., Sugawa, N., James, C. D. & Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl Acad. Sci. USA 89, 4309–4313 (1992). (10.1073/pnas.89.10.4309) / Proc. Natl Acad. Sci. USA by AJ Ekstrand (1992)
  114. Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004). (10.1126/science.1101637) / Science by R Sordella (2004)
  115. Tang, C. K., Gong, X. Q., Moscatello, D. K., Wong, A. J. & Lippman, M. E. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 60, 3081–3087 (2000). / Cancer Res. by CK Tang (2000)
  116. Barber, T. D., Vogelstein, B., Kinzler, K. W. & Velculescu, V. E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351, 2883 (2004). (10.1056/NEJM200412303512724) / N. Engl. J. Med. by TD Barber (2004)
  117. Okamoto, I. et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci. 94, 50–56 (2003). (10.1111/j.1349-7006.2003.tb01351.x) / Cancer Sci. by I Okamoto (2003)
  118. Rosenzweig, K. E., Youmell, M. B., Palayoor, S. T. & Price, B. D. Radiosensitization of human tumor cells by the phosphatidylinositol-3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin. Cancer Res. 3, 1149–1156 (1997). / Clin. Cancer Res. by KE Rosenzweig (1997)
  119. Ng, S. S., Tsao, M. S., Nicklee, T. & Hedley, D. W. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 7, 3269–3275 (2001). / Clin. Cancer Res. by SS Ng (2001)
  120. Kim, S. H. et al. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk. Res. 24, 917–925 (2000). (10.1016/S0145-2126(00)00061-8) / Leuk. Res. by SH Kim (2000)
  121. Schultz, R. M. et al. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 15, 1135–1139 (1995). / Anticancer Res. by RM Schultz (1995)
  122. Hu, L., Zaloudek, C., Mills, G. B., Gray, J. & Jaffe, R. B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 6, 880–886 (2000). / Clin. Cancer Res. by L Hu (2000)
  123. Hu, L., Hofmann, J., Lu, Y., Mills, G. B. & Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087–1092 (2002). / Cancer Res. by L Hu (2002)
  124. Shokat, K. et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12, 4749–4759 (2004). (10.1016/j.bmc.2004.06.022) / Bioorg. Med. Chem. by K Shokat (2004)
  125. Ward, S. G. & Finan, P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3, 426–434 (2003). (10.1016/S1471-4892(03)00078-X) / Curr. Opin. Pharmacol. by SG Ward (2003)
  126. Wymann, M. P., Zvelebil, M. & Laffargue, M. Phosphoinositide 3-kinase signalling — which way to target?, Trends. Pharmacol. Sci. 24, 366–376 (2003). (10.1016/S0165-6147(03)00163-9) / Trends. Pharmacol. Sci. by MP Wymann (2003)
  127. Roberson, A., Jackson, S., Kenche, V., Yaip, C., Parbaharan, H. & Thompson, P. Therapeutic Morpholino-Substituted Compounds. WO 01/53266 A1, Thrombogenix, 2001.
  128. Giranda, V. et al. Novel ATP-competitive Akt inhibitors slow the progression of tumors in vivo. EORTC/AACR Molecular Therapeutics Geneva 2005 Abstract # 246 / EORTC/AACR Molecular Therapeutics by V Giranda (2005)
  129. Defeo-Jones, D. et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 4, 271–279 (2005). (10.1158/1535-7163.271.4.2) / Mol. Cancer Ther. by D Defeo-Jones (2005)
  130. Lindsley, C. W. et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761–764 (2005). (10.1016/j.bmcl.2004.11.011) / Bioorg. Med. Chem. Lett. by CW Lindsley (2005)
  131. Barnett, S. F. et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399–408 (2005). (10.1042/BJ20041140) / Biochem. J. by SF Barnett (2005)
  132. Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A. & Roy, K. K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2, 1093–1103 (2003). / Mol. Cancer Ther. by SB Kondapaka (2003)
  133. Van Ummersen, L. et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. 10, 7450–7456 (2004). (10.1158/1078-0432.CCR-03-0406) / Clin. Cancer Res. by L Van Ummersen (2004)
  134. Eng, C. P., Sehgal, S. N. & Vezina, C. Activity of rapamycin (AY-22, 989) against transplanted tumors. J. Antibiot. (Tokyo) 37, 1231–1237 (1984). (10.7164/antibiotics.37.1231) / J. Antibiot. (Tokyo) by CP Eng (1984)
  135. Dudkin, L. et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7, 1758–1764 (2001). / Clin. Cancer Res. by L Dudkin (2001)
  136. Shi, Y. et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 55, 1982–1988 (1995). / Cancer Res. by Y Shi (1995)
  137. deGraffenried, L. A. et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. 10, 8059–8067 (2004). (10.1158/1078-0432.CCR-04-0035) / Clin. Cancer Res. by LA deGraffenried (2004)
  138. Atkins, M. B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909–918 (2004). (10.1200/JCO.2004.08.185) / J. Clin. Oncol. by MB Atkins (2004)
  139. Chan, S. et al. First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol. 21, abstract 175 (2002).
  140. Galanis, E. et al. NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. 22, 1503 (2004). (10.1200/jco.2004.22.14_suppl.1503) / Proc. Am. Soc. Clin. Oncol. by E Galanis (2004)
  141. DeGraffenried, L. A. et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 15, 1510–1516 (2004). (10.1093/annonc/mdh388) / Ann. Oncol. by LA DeGraffenried (2004)
  142. Mills, G. B., Lu, Y. & Kohn, E. C. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 10031–10033 (2001). (10.1073/pnas.191379498) / Proc. Natl Acad. Sci. USA by GB Mills (2001)
  143. Kau, T. R. et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 4, 463–476 (2003). (10.1016/S1535-6108(03)00303-9) / Cancer Cell. by TR Kau (2003)
  144. Kim, K. M. & Lee, Y. J. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. Oncogene. 24, 355–366 (2005). (10.1038/sj.onc.1208213) / Oncogene. by KM Kim (2005)
  145. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001). (10.1056/NEJM200103153441101) / N. Engl. J. Med. by DJ Slamon (2001)
  146. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004). (10.1126/science.1099314) / Science by JG Paez (2004)
  147. Mukohara, T. et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97, 1185–1194 (2005). (10.1093/jnci/dji238) / J. Natl. Cancer Inst. by T Mukohara (2005)
  148. Haas-Kogan, D. A. et al. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 4, (2005) [Epub ahead of print]. (10.4161/cc.4.10.2105)
  149. Giaccone, G. et al. A phase III clinical trial of ZD 1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT-1). Ann. Oncol. 13, 2 (2002). (10.1093/annonc/mdf663) / Ann. Oncol. by G Giaccone (2002)
  150. Johnson, D. H. et al. ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): initial results from a phase III trial (INTACT-2). Ann. Oncol. 13, 127 (2002). / Ann. Oncol. by DH Johnson (2002)
  151. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004). (10.1056/NEJMoa040938) / N. Engl. J. Med. by TJ Lynch (2004)
  152. Shepherd, F. A. et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc. Am. Soc. Clin. Oncol. 22, 7022 (2004). (10.1200/jco.2004.22.14_suppl.7022) / Proc. Am. Soc. Clin. Oncol. by FA Shepherd (2004)
  153. Moore, M. J. et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Gastrointestinal Cancers Symposium abstract 77 (2005). / ASCO Gastrointestinal Cancers Symposium by MJ Moore (2005)
  154. Kohn, E. C. et al. Targeted Therapeutics in Breast Cancer: Challenges to Success. Diseases of the Breast (Editor Marc Lippman) In Press.
  155. Kohn, E. C. et al. Molecular Therapeutics: promise and challenges. Semin Oncol 31, 39–53 (2004). (10.1053/j.seminoncol.2004.01.009) / Semin Oncol by EC Kohn (2004)
  156. Drees, B. E., Mills, G. B., Rommel, C. & Prestwich G. D. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Expert Opinion on therapeutic patents In Press. (10.1517/13543776.14.5.703)
  157. Meric-Bernstam, F. & Mills, G. B. Mammalian target of rapamycin. Semin Oncol 31 (Suppl. 16), 10–17 (2004). (10.1053/j.seminoncol.2004.10.013) / Semin Oncol by F Meric-Bernstam (2004)
  158. Debiec-Rychter, M. et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128, 270–279 (2005). (10.1053/j.gastro.2004.11.020) / Gastroenterology by M Debiec-Rychter (2005)
  159. Bhalla, U. S., Ram, P. T. & Iyengar, R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 297, 1018–1023 (2002). (10.1126/science.1068873) / Science by US Bhalla (2002)
  160. Bhalla, U. S. & Iyengar, R. Emergent properties of networks of biological signaling pathways. Science 283, 381–387 (1999). (10.1126/science.283.5400.381) / Science by US Bhalla (1999)
  161. Eker, S. et al. Pathway logic: symbolic analysis of biological signaling. Pac Symp Biocomput 400–412 (2002). (10.1142/9789812799623_0038)
  162. Ferrell J. E. Jr., & Machleder, E. M. The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. Science 280, 895–898 (1998). (10.1126/science.280.5365.895) / Science by JE Ferrell Jr. (1998)
  163. Hoffman, A. et al. The IκB–NF–κB signaling module: temporal control and selective gene activation. Science 298, 1241–1245 (2002). (10.1126/science.1071914) / Science by A Hoffman (2002)
  164. Huang, C. Y. & Ferrell, J. E. Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 93, 10078–10083 (1996). (10.1073/pnas.93.19.10078) / Proc. Natl Acad. Sci. USA by CY Huang (1996)
  165. Ma'ayan, A. et al. Formation of regulatory patterns during signal propagation in a Mammalian cellular network. Science 309, 1078–1083 (2005). (10.1126/science.1108876) / Science by A Ma'ayan (2005)
  166. Park, C. S., Schneider, I. C. & Haugh, J. M. Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts. J. Biol. Chem. 278, 37064–37072 (2003). (10.1074/jbc.M304968200) / J. Biol. Chem. by CS Park (2003)
  167. Sachs, K. et al. Causal protein-signaling networks derived from multiparameter single-cell data. Science 308, 523–529 (2005). (10.1126/science.1105809) / Science by K Sachs (2005)
  168. Liu, X. et al. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. Anticancer Res. 24, 2697–2704 (2004). / Anticancer Res. by X Liu (2004)
  169. Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337 (2004). (10.1038/nature02369) / Nature by HG Wendel (2004)
  170. Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc. Natl Acad. Sci. USA 98, 10320–10325 (2001). (10.1073/pnas.171060098) / Proc. Natl Acad. Sci. USA by K Podsypanina (2001)
  171. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314–10319 (2001). (10.1073/pnas.171076798) / Proc. Natl Acad. Sci. USA by MS Neshat (2001)
  172. Pardanani, A. et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104, 3038–3045 (2004). (10.1182/blood-2004-03-0787) / Blood by A Pardanani (2004)
  173. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561–566 (1996). (10.1038/nm0596-561) / Nature Med. by BJ Druker (1996)
  174. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 7, 561–573 (2005). (10.1016/j.ccr.2005.05.014) / Cancer Cell. by Y Samuels (2005)
  175. Lu, Y., Zi, X. & Pollak, M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334–341 (2004). (10.1002/ijc.11445) / Int. J. Cancer by Y Lu (2004)
  176. Ritter, C. A. et al. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. Int. J. Clin. Pharmacol. Ther. 42, 642–643 (2004). (10.5414/CPP42642) / Int. J. Clin. Pharmacol. Ther. by CA Ritter (2004)
  177. Thompson, J. E. & Thompson, C. B. Putting the rap on Akt. J. Clin. Oncol. 22, 4217–4226 (2004). Excellent review of AKT involvement in cancer cell metabolism. (10.1200/JCO.2004.01.103) / J. Clin. Oncol. by JE Thompson (2004)
  178. Warburg, O., Posener, K. & Negelein, E. Uber den stoffwechsel der tumoren. Biochem. Z. 152, 319–344 (1924). / Biochem. Z. by O Warburg (1924)
  179. Rathmell, J. C. et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 23, 7315–7328 (2003). (10.1128/MCB.23.20.7315-7328.2003) / Mol. Cell. Biol. by JC Rathmell (2003)
  180. Bomanji, J. B., Costa, D. C. & Ell, P. J. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2, 157–164 (2001). (10.1016/S1470-2045(00)00257-6) / Lancet Oncol. by JB Bomanji (2001)
  181. Samuelson, A. V. & Lowe, S. W. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proc. Natl Acad. Sci. USA 94, 12094–12099 (1997). (10.1073/pnas.94.22.12094) / Proc. Natl Acad. Sci. USA by AV Samuelson (1997)
  182. George, D. J. & Kaelin, W. G. Jr. The von Hippel–Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. 349, 419–421 (2003). Excellent review of roles of vHL and VEGF in renal cell carcinoma. (10.1056/NEJMp030061) / N. Engl. J. Med. by DJ George (2003)
Dates
Type When
Created 19 years, 8 months ago (Dec. 8, 2005, 4:59 a.m.)
Deposited 8 months ago (Jan. 6, 2025, 4:55 a.m.)
Indexed 13 hours, 13 minutes ago (Sept. 6, 2025, 3:47 p.m.)
Issued 19 years, 9 months ago (Dec. 1, 2005)
Published 19 years, 9 months ago (Dec. 1, 2005)
Published Print 19 years, 9 months ago (Dec. 1, 2005)
Funders 0

None

@article{Hennessy_2005, title={Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery}, volume={4}, ISSN={1474-1784}, url={http://dx.doi.org/10.1038/nrd1902}, DOI={10.1038/nrd1902}, number={12}, journal={Nature Reviews Drug Discovery}, publisher={Springer Science and Business Media LLC}, author={Hennessy, Bryan T. and Smith, Debra L. and Ram, Prahlad T. and Lu, Yiling and Mills, Gordon B.}, year={2005}, month=dec, pages={988–1004} }